Titan Pharmaceuticals (NASDAQ:TTNP) Now Covered by StockNews.com

StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a research note released on Tuesday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Stock Down 7.0 %

NASDAQ TTNP opened at $3.85 on Tuesday. The firm’s 50 day moving average is $3.66 and its 200-day moving average is $4.03. The company has a market capitalization of $3.52 million, a PE ratio of -0.74 and a beta of 1.19. Titan Pharmaceuticals has a 12-month low of $3.03 and a 12-month high of $14.80.

Titan Pharmaceuticals (NASDAQ:TTNP) last issued its quarterly earnings results on Thursday, March 20th. The specialty pharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter.

Titan Pharmaceuticals Company Profile

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.